VIVUS (VVUS) Qsymia Prescriptions Keep Chugging, Gain 27%+ Last Week
Tweet Send to a Friend
VIVUS (Nasdaq: VVUS) is lower Monday amid new data for the fourth-week of its Qsymia roll out showing continued market ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


